We found that IDO1 expression was upregulated in ER-HER2 and HER2 + breast, colon, and endometrial cancers [43], thyroid cancer [44], gastric cancer [45], and gynecological tumors [46]. This evidence concerns the gene ERBB2 and female reproductive system neoplasm.